News | August 08, 2025
Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Subscribe To Our Newsletter & Stay Updated
